RNA-binding protein ENO1 promotes the tumor progression of gastric cancer by binding to and regulating gastric cancer-related genes

Wang, Na; Qiao, Hui; Hao, Jianpeng; Deng, Chenghui; Zhou, Nan; Yang, Liu; Zeng, Miaomiao; Guan, Qun

doi:10.21037/jgo-23-151

Cited by 3 publications

(1 citation statement)

References 22 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High-throughput bioinformatic analysis of thousands of paired tumor and normal samples from the TCGA database revealed a consistent pattern of alterations in RBP expression levels across several cancer types ( 23 , 24 ). In recent years, it has become apparent that the control of gene expression by RBPs is of vital importance in the majority of cellular signaling pathways, extending our understanding of its mechanism as clinical therapeutic targets ( 25 ). However, only a small fraction of RBPs have been deeply studied during the development of cancer ( 26 - 28 ).…”

Section: Discussionmentioning

confidence: 99%

Development and validation of a prognostic model based on RNA binding proteins in patients with esophageal cancer

Du,

Li,

Pang

et al. 2023

J Thorac Dis

View full text Add to dashboard Cite

Background RNA-binding proteins (RBPs) play a crucial role in regulating RNA turnover and are associated with cancer development. However, little is known about the role of RBPs in esophageal cancer (ESCA). The present study focuses on the association between RBP gene expression and survival in ESCA, addressing the clinical relevance of an RBPs-based prediction model for prognosis. Methods RNA-sequencing data and clinical information of patients with ESCA were obtained from The Cancer Genome Atlas (TCGA) database. We identified differentially expressed genes in ESCA and intersected them with RBP-encoding genes. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed with the identified differentially expressed RBPs. Then, a protein-protein interaction (PPI) network was constructed through the STRING database to determine the hub RBPs. Univariate Cox regression analysis and multivariate Cox regression analysis were applied to construct a novel prognostic model based on RBPs. Based on the R package “Caret”, we divided patients into the training set and validation set. The efficacy of the prognostic model was evaluated by the area under the receiver operating characteristic (ROC) curve. A nomogram was developed for the prediction of patient survival outcomes. Results A total of 158 ESCA patients from the TCGA database were included in our analysis. We screened out five prognostic RBPs (CLK1, CIRBP, MRPL13, TNRC6A, and TYW3) through univariate and multivariate Cox regression analysis. CLK1, CIRBP, TNRC6A and TYW3 were downregulated in tumor samples, while MRPL13 was upregulated. A prognostic model constructed with these five RBPs in the training data set accurately stratified ESCA patients into high- and low-risk groups. When the same prognostic model was applied to the test data set and entire cohort, the 5-RBP signature remained an independent prognostic factor in multivariate analysis. The areas under the time-dependent ROC curve of the prognostic model for predicting one-year survival in the training data set, test data set, and entire cohort were 0.789, 0.753, and 0.764, respectively, confirming that this model is a good prognostic model. The nomogram based on the five RBPs and clinical variables could improve individualized outcome predictions and highlight the importance of RBPs in the outcomes of patients with ESCA. Conclusions Our study provides a potential prognostic model for predicting the prognosis of ESCA patients. The prognostic nomogram could improve individualized outcome predictions for patients with ESCA, therefore providing novel insights into future diagnosis and treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Development and validation of a prognostic model based on RNA binding proteins in patients with esophageal cancer

Du,

Li,

Pang

et al. 2023

J Thorac Dis

View full text Add to dashboard Cite

show abstract

Positioning determines function: Wandering PKM2 performs different roles in tumor cells

He,

Liang,

Tan

et al. 2023

Cell Biology International

View full text Add to dashboard Cite

Short for pyruvate kinase M2 subtype, PKM2 can be said of all‐round player that is notoriously known for its metabolic involvement in glycolysis. Holding a dural role as a metabolic or non‐metabolic (kinase) enzyme, PKM2 has drawn extensive attention over its biological roles implicated in tumor cells, including proliferation, migration, invasion, metabolism, and so on. wandering PKM2 can be transboundary both intracellularly and extracellularly. Specifically, PKM2 can be nuclear, cytoplasmic, mitochondrial, exosomal, or even circulate within the body. Importantly, PKM2 can function as an RNA‐binding protein (RBP) to self‐support its metabolic function. Despite extensive investigations or reviews available surrounding the biological roles of PKM2 from different angles in tumor cells, little has been described regarding some novel role of PKM2 that has been recently found, including, for example, acting as RNA‐binding protein, protection of Golgi apparatus, and remodeling of microenvironment, and so forth. Given these findings, in this review, we summarize the recent advancements made in PKM2 research, mainly from non‐metabolic respects. By the way, PKM1, another paralog of PKM2, seems to have been overlooked or under‐investigated since its discovery. Some recent discoveries made about PKM1 are also preliminarily mentioned and discussed.

show abstract

Role of ENO1 and its targeted therapy in tumors

Li,

Liu,

2024

J Transl Med

View full text Add to dashboard Cite

three highly conserved isoforms of enolase in mammals are α-enolase (ENO1), β-enolase (ENO3), and γ-enolase (ENO2). Among them, ENO1 accounts for 90% of the glycolytic pathway's cytosolic enolase activity [3]. Furthermore, ENO1 overexpression is associated with poor prognosis in many types of cancer [4]. ENO2, predominantly localized in the cytoplasm of neurons and neuroendocrine cells, has been identified as a serum marker for tumors of neuronal lineage, such as glioblastoma (GBM) and medulloblastoma [5,6]. Recent studies, however, have revealed that ENO2 is not only highly expressed in neurological tumors but also plays a critical role in the progression of other malignancies, including lung adenocarcinoma (LUAD) and breast cancer. A multiomic analysis demonstrated that 3D tumor spheroid growth implies the overexpression of ENO2 and another glycolytic enzyme, ALDOC, concomitant with the enhanced consumption of glucose and fructose and the enhanced production of lactate, in lung and breast cancer cell lines in different nutrient environmental conditions [7]. ENO3 is predominantly expressed in muscle tissue, with studies indicating that 86% of rhabdomyosarcomas test positive

show abstract

RNA-binding protein ENO1 promotes the tumor progression of gastric cancer by binding to and regulating gastric cancer-related genes

Cited by 3 publications

References 22 publications

Development and validation of a prognostic model based on RNA binding proteins in patients with esophageal cancer

Development and validation of a prognostic model based on RNA binding proteins in patients with esophageal cancer

Positioning determines function: Wandering PKM2 performs different roles in tumor cells

Role of ENO1 and its targeted therapy in tumors

Contact Info

Product

Resources

About